Males and nonpregnant females, ages ≥30 to \<85 years of age at screening
Body weight ≥ 45 kg, BMI \< 40
LVEF ≥ 50%
Diagnosed with Heart Failure per American Heart Association (AHA)/American College of Cardiology (ACC)/Heart Failure Society of America (HFSA) Guidelines for the Management of Heart Failure
New York Heart Association (NYHA) functional class II or III
If receiving Guideline-directed Medical Therapy, must be on stable doses
Participants receiving a GLP-1 agonist prior to Screening must have no anticipated plans to change dose during the study
You may not be if
Known diagnosis of hypertrophic cardiomyopathy (HCM)
Known or suspected infiltrative or storage disorder (e.g., Noonan syndrome, Fabry disease, amyloidosis)
Moderate or greater interstitial lung disease (ILD) or ILD requiring chronic supplemental O2 therapy
Severe or greater chronic obstructive pulmonary disease (COPD) or COPD requiring chronic supplementary O2 therapy
Hospitalization for any reason within 60 days prior to Screening
History or evidence of any other clinically significant disorder, malignancy, active infection, other condition, or disease that, in the opinion of the Investigator or the Medical Monitor, would be an alternative explanation for heart failure symptoms (e.g., significant lung disease, anemia) and/or would pose a risk to patient safety or interfere with the study evaluation, procedures, or completion
Clareo Health | A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
